Sou Hu Cai Jing·2025-08-15 12:39Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Haohai Biological Technology Co., Ltd. in the medical device industry [1][2] - As of August 15, Haohai's stock closed at 55.18 yuan, with a rolling PE ratio of 31.06 times and a total market capitalization of 12.834 billion yuan [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Haohai at the 60th position in the industry ranking [1][2] Group 2 - As of February 29, 2020, Haohai had 7,605 shareholders, an increase of 918 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business includes the research, production, and sales of medical devices and pharmaceuticals, with key products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1] - In the latest quarterly report for Q1 2025, Haohai reported revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41%, with a gross profit margin of 69.52% [1]